DZ2199A1 - Dihydrate d'éprosartan et son procédé de préparation et sa formulation. - Google Patents

Dihydrate d'éprosartan et son procédé de préparation et sa formulation.

Info

Publication number: DZ2199A1
Authority: DZ; Algeria
Prior art keywords: formulation; preparation process; eprosartan; dihydrate; eprosartan dihydrate
Prior art date: 1996-03-29

Application number

DZ970046A

Other languages

English (en)

Inventor

Nagesware R Palepu

Gopadi M Venkatesh

Sarma Duddu

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-29

Filing date

1997-03-29

Publication date

2002-12-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ2199(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-03-29 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2002-12-03 Application granted granted Critical

2002-12-03 Publication of DZ2199A1 publication Critical patent/DZ2199A1/fr

Links

239000002080 C09CA02 - Eprosartan Substances 0.000 title 1
-1 Eprosartan dihydrate Chemical class 0.000 title 1
229960004563 eprosartan Drugs 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
238000002360 preparation method Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DZ970046A 1996-03-29 1997-03-29 Dihydrate d'éprosartan et son procédé de préparation et sa formulation. DZ2199A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US1441496P	1996-03-29	1996-03-29

Publications (1)

Publication Number	Publication Date
DZ2199A1 true DZ2199A1 (fr)	2002-12-03

Family

ID=21765344

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ970046A DZ2199A1 (fr)	1996-03-29	1997-03-29	Dihydrate d'éprosartan et son procédé de préparation et sa formulation.

Country Status (35)

Country	Link
EP (1)	EP0889880B1 (fr)
JP (1)	JP4316013B2 (fr)
CN (2)	CN1214682A (fr)
AP (1)	AP901A (fr)
AR (1)	AR006439A1 (fr)
AT (1)	ATE239723T1 (fr)
AU (1)	AU726694B2 (fr)
BG (1)	BG64095B1 (fr)
BR (1)	BR9708336A (fr)
CA (1)	CA2250395C (fr)
CZ (1)	CZ293345B6 (fr)
DE (1)	DE69721749T2 (fr)
DK (1)	DK0889880T3 (fr)
DZ (1)	DZ2199A1 (fr)
EA (1)	EA001958B1 (fr)
EG (1)	EG23889A (fr)
ES (1)	ES2198564T3 (fr)
HU (1)	HU228263B1 (fr)
ID (1)	ID16507A (fr)
IL (1)	IL126319A0 (fr)
MA (1)	MA24437A1 (fr)
MY (1)	MY117682A (fr)
NO (2)	NO311760B1 (fr)
NZ (1)	NZ332008A (fr)
OA (1)	OA11176A (fr)
PL (1)	PL188816B1 (fr)
PT (1)	PT889880E (fr)
RO (1)	RO118870B1 (fr)
SK (1)	SK282346B6 (fr)
TR (1)	TR199801954T2 (fr)
TW (1)	TW434239B (fr)
UA (1)	UA49880C2 (fr)
UY (1)	UY24504A1 (fr)
WO (1)	WO1997036874A1 (fr)
ZA (1)	ZA972686B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0991647B1 (fr) *	1997-06-27	2002-09-04	Smithkline Beecham Corporation	Eprosartane monohydrate
US6558699B2 (en) *	1997-11-17	2003-05-06	Smithkline Beecham Corporation	High drug load immediate and modified release oral dosage formulations and processes for their manufacture
PL340587A1 (en) *	1997-11-17	2001-02-12	Smithkline Beecham Corp	Oral preparations of high therapeutic substance content with instantaneous or modifiable release of such substance and methods of obtaining them
ES2214013T3 (es)	1998-03-04	2004-09-01	Takeda Chemical Industries Ltd	Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso.
ZA991922B (en) *	1998-03-11	1999-09-13	Smithkline Beecham Corp	Novel compositions of eprosartan.
AU763309B2 (en) *	1998-07-20	2003-07-17	Smithkline Beecham Corporation	Bioenhanced formulations comprising eprosartan in oral solid dosage form
GB9820405D0 (en) *	1998-09-18	1998-11-11	Smithkline Beecham Plc	Process
WO2000027397A1 (fr) *	1998-11-06	2000-05-18	Glaxo Group Limited	Medicaments antihypertenseurs a base de lacidipine et de telmisartan
WO2000027396A1 (fr) *	1998-11-06	2000-05-18	Glaxo Group Limited	Medicaments a base de combinaisons de lacidipine et de telmisartan ou de derives physiologiques
WO2000066161A1 (fr) *	1999-04-28	2000-11-09	Takeda Chemical Industries, Ltd.	Preventifs / remedes / inhibiteurs de progression pour retinopathie simplex ou retinopathie preproliferante
GB9920917D0 (en)	1999-09-03	1999-11-10	Sb Pharmco Inc	Novel process
GB9920919D0 (en)	1999-09-03	1999-11-10	Sb Pharmco Inc	Novel compound
CA2405793A1 (fr) *	2000-04-12	2001-10-18	Novartis Ag	Combinaison de composes organiques
PL370270A1 (en) *	2001-11-23	2005-05-16	Solvay Pharmaceuticals Gmbh	Hypertonia treatment during the acute phase of a cerebrovascular accident
KR100517638B1 (ko)	2002-04-08	2005-09-28	주식회사 엘지생명과학	게미플록사신 산염의 새로운 제조방법
EG24716A (en)	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
WO2003097099A1 (fr) *	2002-05-17	2003-11-27	Novartis Ag	Combinaison de bloquants du recepteur d'angiotensine ii et de betabloquants pour la prevention secondaire d'infarctus du myocarde
DE10230272A1 (de) *	2002-07-05	2004-01-22	Solvay Pharmaceuticals Gmbh	AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
RS20050590A (sr)	2003-01-31	2007-09-21	Sankyo Company Limited,	Lek za profilaksu i tretman arterioskleroze i hipertenzije
US8361507B2 (en)	2007-07-25	2013-01-29	Hetero Drugs Limited	Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
WO2009084028A2 (fr) *	2007-12-03	2009-07-09	Neuland Laboratories Ltd	Procédé amélioré de fabrication de méthanesulfonate de l'acide (e)-3-[2-butyl-1-{(4-carboxyphényl)méthyl}-1h-imidazol-5-yl]-(thiophén-2-ylméthyl)prop-2-énoïque
CN101333216A (zh) *	2008-08-03	2008-12-31	浙江华海药业股份有限公司	一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) *	2021-06-03	2023-09-15	北京宝诺康医药科技有限公司	一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5312828A (en) *	1989-06-14	1994-05-17	Finkelstein Joseph A	Substituted imidazoles having angiotensin II receptor blocking activity
US5185351A (en) *	1989-06-14	1993-02-09	Smithkline Beecham Corporation	Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
EP0563238B1 (fr) *	1990-12-14	2002-05-22	Smithkline Beecham Corporation	Acides imidazolyl-alcenoiques

1997
- 1997-03-26 AR ARP970101257A patent/AR006439A1/es active IP Right Grant
- 1997-03-26 IL IL12631997A patent/IL126319A0/xx active IP Right Grant
- 1997-03-26 ES ES97917004T patent/ES2198564T3/es not_active Expired - Lifetime
- 1997-03-26 PT PT97917004T patent/PT889880E/pt unknown
- 1997-03-26 CZ CZ19983101A patent/CZ293345B6/cs not_active IP Right Cessation
- 1997-03-26 HU HU9902769A patent/HU228263B1/hu unknown
- 1997-03-26 WO PCT/US1997/004877 patent/WO1997036874A1/fr not_active Ceased
- 1997-03-26 EP EP97917004A patent/EP0889880B1/fr not_active Expired - Lifetime
- 1997-03-26 CN CN97193471A patent/CN1214682A/zh active Pending
- 1997-03-26 AT AT97917004T patent/ATE239723T1/de active
- 1997-03-26 NZ NZ332008A patent/NZ332008A/xx not_active IP Right Cessation
- 1997-03-26 DE DE69721749T patent/DE69721749T2/de not_active Expired - Lifetime
- 1997-03-26 PL PL97329046A patent/PL188816B1/pl unknown
- 1997-03-26 EA EA199800873A patent/EA001958B1/ru not_active IP Right Cessation
- 1997-03-26 BR BR9708336A patent/BR9708336A/pt not_active IP Right Cessation
- 1997-03-26 DK DK97917004T patent/DK0889880T3/da active
- 1997-03-26 UA UA98095006A patent/UA49880C2/uk unknown
- 1997-03-26 AU AU25470/97A patent/AU726694B2/en not_active Expired
- 1997-03-26 RO RO98-01406A patent/RO118870B1/ro unknown
- 1997-03-26 MA MA24539A patent/MA24437A1/fr unknown
- 1997-03-26 JP JP53538497A patent/JP4316013B2/ja not_active Expired - Lifetime
- 1997-03-26 TR TR1998/01954T patent/TR199801954T2/xx unknown
- 1997-03-26 UY UY24504A patent/UY24504A1/es not_active IP Right Cessation
- 1997-03-26 SK SK1322-98A patent/SK282346B6/sk not_active IP Right Cessation
- 1997-03-26 CA CA002250395A patent/CA2250395C/fr not_active Expired - Lifetime
- 1997-03-27 MY MYPI97001335A patent/MY117682A/en unknown
- 1997-03-27 EG EG24497A patent/EG23889A/xx active
- 1997-03-27 AP APAP/P/1997/000956A patent/AP901A/en active
- 1997-03-27 ZA ZA9702686A patent/ZA972686B/xx unknown
- 1997-03-29 DZ DZ970046A patent/DZ2199A1/fr active
- 1997-03-31 ID IDP971059A patent/ID16507A/id unknown
- 1997-06-17 TW TW086108370A patent/TW434239B/zh not_active IP Right Cessation
1998
- 1998-09-28 NO NO19984503A patent/NO311760B1/no not_active IP Right Cessation
- 1998-09-29 OA OA9800184A patent/OA11176A/en unknown
- 1998-10-07 BG BG102822A patent/BG64095B1/bg unknown
2001
- 2001-06-09 CN CN01121133A patent/CN1332167A/zh active Pending
2002
- 2002-07-19 NO NO2002005C patent/NO2002005I1/no unknown

Also Published As

Publication number	Publication date
PL188816B1 (pl)	2005-04-29
AR006439A1 (es)	1999-08-25
DK0889880T3 (da)	2003-09-01
HUP9902769A3 (en)	2000-04-28
CZ293345B6 (cs)	2004-04-14
BG64095B1 (bg)	2003-12-31
SK132298A3 (en)	1999-03-12
HUP9902769A2 (hu)	2000-03-28
IL126319A0 (en)	1999-05-09
DE69721749D1 (de)	2003-06-12
EG23889A (en)	2007-12-12
AU2547097A (en)	1997-10-22
PL329046A1 (en)	1999-03-01
TW434239B (en)	2001-05-16
JP2000508632A (ja)	2000-07-11
NO984503L (no)	1998-09-28
AP901A (en)	2000-11-23
UY24504A1 (es)	1997-09-19
PT889880E (pt)	2003-09-30
SK282346B6 (sk)	2002-01-07
EP0889880A1 (fr)	1999-01-13
HK1016594A1 (en)	1999-11-05
BR9708336A (pt)	1999-08-03
EA199800873A1 (ru)	1999-02-25
OA11176A (en)	2003-05-13
CZ310198A3 (cs)	1999-03-17
HU228263B1 (en)	2013-02-28
DE69721749T2 (de)	2004-03-25
CA2250395C (fr)	2005-09-06
NO311760B1 (no)	2002-01-21
NO2002005I1 (no)	2002-09-02
CN1332167A (zh)	2002-01-23
MA24437A1 (fr)	1998-10-01
WO1997036874A1 (fr)	1997-10-09
BG102822A (en)	1999-11-30
AU726694B2 (en)	2000-11-16
AP9700956A0 (en)	1997-04-30
TR199801954T2 (xx)	1998-12-21
JP4316013B2 (ja)	2009-08-19
UA49880C2 (uk)	2002-10-15
EA001958B1 (ru)	2001-10-22
ZA972686B (en)	1997-09-29
ID16507A (id)	1997-10-02
MY117682A (en)	2004-07-31
CN1214682A (zh)	1999-04-21
ATE239723T1 (de)	2003-05-15
EP0889880B1 (fr)	2003-05-07
ES2198564T3 (es)	2004-02-01
RO118870B1 (ro)	2003-12-30
NO984503D0 (no)	1998-09-28
NZ332008A (en)	1999-05-28
CA2250395A1 (fr)	1997-10-09
EP0889880A4 (fr)	1999-06-23

Publication	Publication Date	Title
MA24437A1 (fr)	1998-10-01	Procede de la preparation et de la formulation de dihydrate d'eprosartan
DZ1880A1 (fr)	2002-02-17	Forme posologique d'azithromycine et son procédé de production.
OA08743A (fr)	1989-03-31	Dihydrate d'azithromycine et son procédé de préparation.
MA24800A1 (fr)	1999-12-31	Agent de blanchiment et son procede de preparation
FI951226L (fi)	1995-03-16	Hydrogeelityyppinen hitaasti vapauttava preparaatti
DZ1878A1 (fr)	2002-02-17	Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2718450B1 (fr)	1997-01-10	Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
NO981800L (no)	1998-06-11	FremgangsmÕte for fremstilling av 1,1,1,3,3-pentafluorpentan
HUP9903459A3 (en)	2001-08-28	Oxa- and tiabicyclo[3.1.0]hexane-carboxylic acids, process for their preparation and pharmaceutical compositions of the same
FR2732343B1 (fr)	1997-06-13	Composition de maltitol et son procede de preparation
HUP9602868A3 (en)	2000-02-28	1,7,7-trimethyl-bicyclo[2.2.1]heptane derivative, pharmaceutical compositions containing the same and process for their preparation
EP0657438A3 (fr)	1995-10-11	Procédé pour la préparation d'alkylesulfinylbenzamides et de 1,2-benzoisothiazol-3-ones.
EP0659779A3 (fr)	1996-05-22	Microsphères et procédé de leur préparation.
EE03438B1 (et)	2001-06-15	Felodipiini valmistamise protsess
DZ2418A1 (fr)	2003-06-26	Procédé de préparation d'éprosartan
FR2708266B1 (fr)	1997-01-10	Procédé de préparation d'alcanesulfonamides.
NO985535L (no)	1999-01-27	FremgangsmÕte for fremstilling av 1,3-alkandioler
DZ2770A1 (fr)	2003-12-01	Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
FR2716203B1 (fr)	1997-09-12	Procédé de préparation de violanthrones ou d'isoviolanthrones chlorées.
EP0837129A4 (fr)	2004-11-24	Antagoniste de l'epimorphine et son procede de fabrication
FR2778917B1 (fr)	2000-06-30	Nouveaux derives d'histidine, procede de preparation et utilisations
EP0622396A3 (fr)	1995-09-06	Polysilanes et leur procédé de préparation.
FI964829A0 (fi)	1996-12-03	Menetelmä 2,2,4-trimetyyli-1,3-pentaanidioli-isobutyraatin valmistamiseksi
FR2719308B1 (fr)	1997-08-22	Dérivés de purpurogalline et son procédé d'obtention.
EP0643139A3 (fr)	1996-06-26	Procédé de préparation d'indigo.